SynAct Pharma AB (SYNACT) — Cash Flow-to-Debt Ratio
SynAct Pharma AB (SYNACT) has a Cash Flow-to-Debt Ratio of -0.48x as of December 2025, meaning its operating cash flow of Skr-23.96 Million could theoretically repay 0% of its total liabilities (Skr50.23 Million) in one year. See SYNACT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SynAct Pharma AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for SynAct Pharma AB across 10 annual periods. Also explore SynAct Pharma AB (SYNACT) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SynAct Pharma AB (2016–2025)
Year-by-year debt coverage analysis for SynAct Pharma AB. For market capitalisation and broader financial context, see market value of SynAct Pharma AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.94x | Skr-97.33 Million | Skr50.23 Million | ▼ -22.4% |
| 2024 | -1.58x | Skr-89.20 Million | Skr56.35 Million | ▲ +18.1% |
| 2023 | -1.93x | Skr-100.18 Million | Skr51.83 Million | ▲ +73.6% |
| 2022 | -7.31x | Skr-117.56 Million | Skr16.08 Million | ▼ -96.9% |
| 2021 | -3.71x | Skr-65.00 Million | Skr17.50 Million | ▲ +36.0% |
| 2020 | -5.81x | Skr-33.24 Million | Skr5.72 Million | ▼ -271.3% |
| 2019 | -1.56x | Skr-16.12 Million | Skr10.31 Million | ▲ +76.0% |
| 2018 | -6.52x | Skr-24.21 Million | Skr3.72 Million | ▲ +12.4% |
| 2017 | -7.44x | Skr-17.20 Million | Skr2.31 Million | ▼ -76.3% |
| 2016 | -4.22x | Skr-14.73 Million | Skr3.49 Million | — |